In a cross-sectional study on NAFLD, non-diabetic patients found a positive association of CK18 with serum ALT.38 RCTs using T2DM patients having NAFLD can give further evidence of this cost-effective non-invasive approach for improved management of twin comorbidities. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatotic liver disease.